Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Key facts

Sponsor

Stanford University

Principal Investigator

Laura Johnston

Stanford University

Intervention

Sirolimus(drug)

Enrollment

11 enrolled

Eligibility

2-60 years · All sexes

Timeline

2006 – 2010

Study locations (1)

• Stanford University School of Medicine, Stanford, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Macrophagic myofasciitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06973668
  A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
  M.D. Anderson Cancer Center

See all trials for Macrophagic myofasciitis →